These agents include imatinib for the treatment of myeloid leukemia, trastuzumab directed at the human epidermal growth factor receptor 2 (HER2) expressed in some patients with breast cancer, and vemurafenib for melanoma expressing a mutant BRAF gene [18,19,20]. This evidence concerns the gene ERBB2 and myeloid leukemia.